Promising combo tackles relapsed myeloma in early trial
NCT ID NCT01615029
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called daratumumab, given together with two standard treatments (lenalidomide and dexamethasone), in 45 people whose multiple myeloma had returned or stopped responding to prior therapy. The main goal was to check safety and see how many patients responded to the combination. The trial was completed and helped determine the best dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daratumumab (a targeted antibody) combined with lenalidomide and dexamethasone
What this could lead to
If successful, this combination could offer a new treatment option for people with multiple myeloma that has returned or stopped responding to prior therapies.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply to all patients. Side effects from the drug combination could be significant, and the treatment is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Boston, Massachusetts, United States
-
Study site
Copenhagen Ø, Denmark
-
Study site
Vejle, Denmark
-
Study site
Lille, France
-
Study site
Nantes, France
-
Study site
Vandœuvre-lès-Nancy, France
-
Study site
Utrecht, Netherlands
-
Study site
London, United Kingdom